Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aldara Keratosis Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

3M's Aldara supplemental NDA cleared FDA March 2 for the treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults

You may also be interested in...



PhotoCure/Galderma Actinic Keratosis Phototherapy Clears FDA

The PhotoCure product, marketed as Metvix outside the U.S., will be launched by partner Galderma in “several weeks” following selection of an alternate tradename. The methyl aminolevulinate cream is used in combination with the CureLight activation lamp.

PhotoCure/Galderma Actinic Keratosis Phototherapy Clears FDA

The PhotoCure product, marketed as Metvix outside the U.S., will be launched by partner Galderma in “several weeks” following selection of an alternate tradename. The methyl aminolevulinate cream is used in combination with the CureLight activation lamp.

Aldara For Basal Cell Carcinoma

3M's Aldara received a supplemental approval for the treatment of superficial basal cell carcinoma July 14

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel